This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Taieb, D. Articles by Soubeyran, P. Search for Related Content PubMed PubMed Citation Articles by Taieb, D. Articles by Soubeyran, P.

ArgBP2-Dependent Signaling Regulates Pancreatic Cell Migration, Adhesion, and Tumorigenicity

¹ INSERM U.624; ² FRE CNRS 2737, Faculté de Pharmacie, Université de la Méditerranée; and ³ INSERM U.600, Marseille, France

Requests for reprints: Philippe Soubeyran, INSERM U.624, 163 Avenue de Luminy, Case 915, 13288 Marseille cedex 9, France. Phone: 33-491-827564; Fax: 33-491-826083; E-mail: soubeyran{at}marseille.inserm.fr.

The poor prognosis of pancreatic cancer is due to rapid locoregional invasion, the early development of metastases, and the limited efficacy of current therapies. To date, none of the identified oncogenes and suppressors involved in this disease have led to efficient treatments. Here, we describe that the scaffold protein ArgBP2 is repressed during oncogenic transformation of the pancreas. We could show, using a pancreatic cancer cell line model, that this repression of ArgBP2 participates in the progression of this disease. Interestingly, in vitro analyses revealed that the antitumoral potential of ArgBP2 is linked to the control of cell adhesion and migration rather than to the regulation of cell proliferation or sensitivity to apoptosis. Moreover, we could detail part of the molecular mechanism responsible by identifying new ArgBP2-interacting proteins, and show that this function is partly achieved by the control of a WAVE/PTP-PEST/c-Abl signaling complex. These findings point to a new mechanism of pancreatic cancer progression leading to invasion and metastasis and suggest that the ArgBP2 signaling pathway could represent a new target for cancer therapy. [Cancer Res 2008;68(12):4588–96]